

A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children

Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, Busse GD, Cutler AJ, Jones NJ, Findling RL, Schwabe S.

Clinical therapeutics

2020; 42(8):1452-1466

ARTICLE IDENTIFIERS

DOI: 10.1016/j.clinthera.2020.05.021

PMID: 32723670

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: not available

pISSN: 0149-2918

eISSN: 1879-114X

OCLC ID: not available

CONS ID: not available

US National Library of Medicine ID: 7706726

This article was identified from a query of the SafetyLit database.